Last checked at 8 Dec 2020 14:42
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Result of Annual General Meeting
8 December 2020 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that, with the exception of resolution 10, which failed to carry, all other resolutions proposed at the 2020 Annual General Meeting ("AGM") were duly passed by shareholders. Voting was conducted by way of a poll.
Resolutions 1 to 9 (inclusive) were proposed as ordinary resolutions and resolution 10 was proposed as a special resolution. The results of the poll are outlined in the table below.
The Board acknowledges the failure to pass resolution 10 and is disappointed in this outcome. The Board considers the flexibility afforded by these authorities to be in the best interests of the Company and shareholders and notes that this resolution has received support at previous AGMs. However, the Board remains committed to continuing an open and transparent dialogue and will, accordingly, seek to continue to engage with shareholders regarding their views in this area.
Resolution | For: | %age | Against: | %age | Total Votes Cast | % of ISC | Withheld |
1. to receive a copy of the Annual Report for the year ended 30 June 2020 | 556,845,254 | 100 | 0 | 0 | 556,845,254 | 87.03 | 26,857 |
2. To approve the Directors' Remuneration Report | 554,801,389 | 99.64 | 1,990,053 | 0.36 | 556,791,442 | 87.02 | 80,669 |
3. To re-appoint Manuel Llobet as a Director | 556,845,611 | 100 | 0 | 0 | 556,845,611 | 87.03 | 26,500 |
4. To re-appoint Nicolas Wykeman as a Director | 556,821,111 | 99.99 | 25,000 | 0.01 | 556,846,111 | 87.03 | 26,000 |
5. To re-appoint Steve Smith as a Director | 554,199,787 | 99.53 | 2,636,967 | 0.47 | 556,836,754 | 87.02 | 35,357 |
6. To re-appoint Peter Jensen as a Director | 554,200,287 | 99.6 | 2,211,900 | 0.4 | 556,412,187 | 86.96 | 459,924 |
7. To re-appoint Grant Thornton LLP as auditors of the Company | 554,851,201 | 99.64 | 2,007,553 | 0.36 | 556,858,754 | 87.03 | 13,357 |
8. To authorise the Directors to determine the Auditors remuneration | 556,787,942 | 99.99 | 25,000 | 0.01 | 556,812,942 | 87.02 | 59,169 |
9. To authorise the Directors to allot the unissued share capital up to a specified amount (s.551) | 281,855,864 | 50.8 | 272,997,694 | 49.2 | 554,853,558 | 86.71 | 2,018,553 |
10. Special Resolution: To disapply pre-emption provisions of s.561(1) of the Companies Act 2006 up to a specified amount | 281,828,810 | 50.61 | 274,980,390 | 49.39 | 556,809,200 | 87.02 | 62,911 |
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Deardon, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Ashley Tapp / Olivia Manser
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines, that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.